Anapol Weiss lawyer joins New Jersey GLP-1 vision loss leadership team

Anapol Weiss shareholder Tracy A. Finken was appointed to the Plaintiffs’ Executive Committee in New Jersey litigation over alleged GLP-1-related NAION vision injuries. The June 9 court order in Bergen County sets the plaintiffs’ leadership structure in a case that could shape how similar claims move forward.

Why it matters: - The appointment puts Anapol Weiss in a key leadership role in a multicounty case involving allegations that GLP-1 medications are linked to non-arteritic anterior ischemic optic neuropathy, or NAION. - NAION can cause sudden and potentially permanent vision loss, making the litigation high-stakes for patients and drug makers alike. - The leadership structure may influence how claims are coordinated, how evidence is developed and how the case advances in New Jersey.

What happened: - Hon. Gregg A. Padovano, J.S.C. signed an order on June 9, 2026, in Superior Court of New Jersey, Law Division, Bergen County. - The order appointed Tracy A. Finken, shareholder at Anapol Weiss, to the Plaintiffs’ Executive Committee in the New Jersey GLP-1 Medications – Non-Arteritic Anterior Ischemic Optic Neuropathy Vision Loss Multicounty Litigation. - Finken is one of four attorneys selected for the Executive Committee. - The litigation carries Master Docket No. BER-L-3317-26.

The details: - The plaintiffs allege that GLP-1 receptor agonist medications are associated with serious vision injuries, including NAION. - The case was designated for Multicounty Litigation status under the New Jersey Supreme Court’s order of Oct. 16, 2025. - The court also named Ellen Relkin of Weitz & Luxenberg and Adam Slater of Mazie Slater Katz & Freeman as Plaintiffs’ Lead Counsel. - Danielle Gold of Weitz & Luxenberg was appointed Plaintiffs’ Liaison Counsel. - Finken will serve with Matt Morrison of Harrison Davis Morrison Jones, Shannon Pennock of Morgan & Morgan and David Rosenband of The Lanier Law Firm on the Executive Committee.

Between the lines: - The appointment signals that New Jersey courts are moving the litigation into a more formal leadership phase. - Concentrating leadership in a small committee can speed coordination across related claims and streamline strategy. - Finken’s placement on the committee gives Anapol Weiss a direct role in shaping the plaintiffs’ approach in a developing drug-injury case.

What’s next: - The plaintiffs’ leadership team is expected to organize discovery, coordinate filings and manage case strategy. - The litigation will continue under the newly established leadership structure in Bergen County. - Finken said patients who developed serious vision loss after taking a GLP-1 medication deserve answers and strong representation, and she expects to work with the committee to advance the cases.